ERNA · Amended Registration Statement (Form S-1/A) · Filed February 4, 2026

Ernexa Therapeutics Inc — S-1/A exhibit

ex107.htm

Ernexa Therapeutics Inc on Boardroom Alpha

EXHIBIT 107

Calculation of Filing Fee Table

Form S-1

(Form Type)

333-293150

Ernexa Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

	Security Type	Security Class Title	Fee Calculation Rule	Amount to be Registered		Proposed Maximum Offering Price Per Unit		Proposed Maximum Aggregate Offering Price		Fee Rate		Amount of Registration Fee
Fees to Be Paid	Equity	Common Stock, par value $0.005 per share	Rule 457(o)			$		$	12,500,000		0.0001381	$	1,726.25
	Equity	Common Stock, issuable to Placement Agent as Agent’s Shares	Rule 457(o)			$		$	187,500		0.0001381	$	25.89
	Equity	Common Warrants to purchase Common Stock	Other ⁽¹⁾		-		-		-		0.0001381-		-
	Equity	Common stock issuable upon exercise of the Common Warrants	Rule 457(o)			$		$	12,500,000		0.0001381	$	1,726.25
Total Offering Amounts								$	25,187,500			$	3,478.39
Total Fees Previously Paid												$	5,565.43
Total Fee Offsets												$	-
Net Fee Due												$	-

(1)	In accordance with Rule 457(g) under the Securities Act, because the Common Stock of the registrant underlying the Common Warrants are registered hereby, no separate registration fee is required with respect to the Common Warrants registered hereby.

N/A

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer